Kornimate/medical-research-clean huggingface dataset:
anlotinib retrospective study for esophageal cancer

Conditions: Esophageal Neoplasms

Summary: the efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. the purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.


Eligibility criteria:
inclusion criteria: * esophageal cancer diagnosed pathologically or clinically * patients who use anlotinib alone, or combined with chemoradiotherapy, or plus pd-1 inhibitors in first-line or second-line treatment exclusion criteria: none
pyrotinib combined with trastuzumab and chemotherapy in her2-positive mbc

Conditions: HER2-positive Breast Cancer; Metastatic Breast Cancer

Summary: to explore the real world data of trastuzumab combined with trastuzumab and chemotherapy in china, and to explore the relationship between progression free survival and treatment pattern.


Eligibility criteria:
inclusion criteria: * woman, age \> 18 years old * diagnosed with her2 +metastatic breast cancer * pyrotinib combined with trastuzumab and chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31 * available medical history exclusion criteria: * incomplete medical history
en3835 for the treatment of edematous fibrosclerotic panniculopathy (commonly known as cellulite)

Conditions: Edematous Fibrosclerotic Panniculopathy; Cellulite

Summary: the study will evaluate the safety, effectiveness, and immunogenicity of en3835 in the treatment of adult women with edematous fibrosclerotic panniculopathy (commonly known as cellulite).


Eligibility criteria:
inclusion criteria: * be a female ≥18 years of age * at screening visit, have at least 1 quadrant with: * a score of 3 or 4 (moderate or severe) as reported by the subject (pr- pcss), and * a score of 3 or 4 (moderate or severe) as reported by the investigator (cr-pcss), and * a hexsel css score no greater than 13 * at day 1 visit, have an assigned quadrant with: * a score of 3 or 4 (moderate or severe) as reported by the subject (pr-pcss), and * a score of 3 or 4 (moderate or severe) as reported by the investigator (cr-pcss), and * a hexsel css score no greater than 13 * be willing to apply sunscreen to the selected treatment quadrant before each exposure to the sun while participating in the study (ie, screening through end of study). * be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening * have a negative urine pregnancy test at screening and be using an effective contraception method (eg, abstinence, intrauterine device \[iud\], hormonal \[estrogen/progestin\] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the investigator; or post-menopausal for at least 1 year; or be surgically sterile. * be willing and able to cooperate with the requirements of the study * voluntarily sign and date an informed consent agreement approved by the institutional review board/independent ethics committee/human research ethics committee (irb/iec/hrec). * be able to read, complete and understand the patient reported outcomes rating instruments in english exclusion criteria: * has any of the following conditions: * thyroid disease, unless controlled with medication for ≥6 months * uncontrolled diabetes mellitus, as determined by the investigator * uncontrolled hypertension, as determined by the investigator * vascular disorder (eg, phlebitis or varicose veins) in area to be treated * cushing's disease and/or use of systemic corticosteroids at a total daily dose greater than 5 mg prednisone (or equivalent) * history of lower extremity thrombosis or post-thrombosis syndrome * documented autoimmune disorder such as lupus erythematosus, rheumatoid arthritis * inflammation or active infection in area to be treated * active cutaneous alteration in area to be treated including rash, eczema, psoriasis or skin cancer * history of keloidal scarring or abnormal wound healing * coagulation disorder * taking a medication for chronic anticoagulation (except for ≤150 mg aspirin daily)
placebo and active controlled study to compare the antipyretic efficacy of aspirin® in patients with acute febrile upper respiratory tract infections suspected to be of viral origin

Conditions: Respiratory Tract Infections; Fever

Summary: this study is addressed to patients suffering from an acute febrile upper respiratory tract infection suspected to be of viral origin. the purpose of this study is to determine the antipyretic efficacy (reduction of fever by lowering the body temperature from a raised state) of aspirin in doses of 500 and 1000 mg (study medication) compared to the one of paracetamol in doses of 500 and 1000 mg (comparator medication) as well as the one of placebo (comparator medication without an active substance). despite of its common use for fever treatment, the scientific data in adults which support the antipyretic efficacy of aspirin are sparse. therefore, the purpose of this study is to collect such data.


Eligibility criteria:
inclusion criteria: * ambulatory male or female patients 18 to 65 years of age * acute uncomplicated febrile urti suspected to be of viral origin and present not more than 5 days * symptoms of a viral urti * oral temperature \>/= 38.5 °c to \</= 40°c exclusion criteria: * patients with physical findings consistent with the diagnosis of pneumonia, otitis media, bacterial sinusitis or any other bacterial infection of the respiratory tract requiring antibiotics or other therapeutic intervention by a physician * current antibiotic treatment or pre-treatment with antibiotic agents during the last week * history or presence of asthma or hypersensitivity to asa, salicylates, paracetamol, or other non-steroidal anti-inflammatory drugs; peptic ulceration or gastric bleeding; hemorrhagic diathesis; hepatic and/or renal dysfunction; gilbert's disease; quincke's edema * any other acute or chronic disease which in the opinion f the investigator could interfere with the patient's health and well-being during the conduct of the study or which could interfere with the evaluation of data generated from this subject * any conditions possibly interfering with the gastro-intestinal absorption of the study medication * pregnant or lactating women. all women of childbearing age were to undergo a pregnancy test before start of the study

Keywords: upper respiratory tract infections
satisfaction/quality of life with rivaroxaban in dvt (deep venous thrombosis) indication

Conditions: Venous Thrombosis

Summary: national, multicenter, prospective, observational, non-interventional study. the objective is to determine if the switch from vitamin k antagonists (vka) to xarelto in subjects treated with vka with issues in deep venous thrombosis (dvt), and prevention of recurrent dvt and pulmonary embolism (pe) is associated with an improvement of the treatment satisfaction after 3 months. the treatment satisfaction will be measured by the anti clot treatment scale (acts) score.


Eligibility criteria:
inclusion criteria: * female or male subject ≥ 18 years of age, * with a diagnosis of acute dvt treated with vka with issues for at least the 4 previous weeks (issues are assessed on medical judgment) * who intends to start rivaroxaban for treatment of deep vein thrombosis (dvt), and prevention of recurrent dvt and pulmonary embolism (pe) following an acute dvt * with anticoagulation therapy planned for at least 3 months exclusion criteria: * contra indication to the use of xarelto as described in the summary of product characteristics (smpc); key contra indications are: * hypersensitivity to the active substance or to any of the excipients listed in smpc section 6.1. * lesion or condition at significant risk of major bleeding * concomitant treatment with any other anticoagulant agent * clinically significant active bleeding * hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c * pregnancy and breast feeding

Keywords: sf36 questionnaire anti clot treatment scale satisfaction quality of life rivaroxaban prevention & control pulmonary embolism
recurrence and bleeding in colorectal cancer patients with cancer-associated venous thrombembolism

Conditions: Thrombosis, Venous; Colo-rectal Cancer; Bleeding

Summary: patients with colorectal cancer (crc) have a higher risk of both venous thromboembolism (vte) and major bleeding (mb). patients with crc are underrepresented in the major trials examining treatment of cancer-associated vte with anticoagulant.

patients with colorectal cancer (crc) have a higher risk of both venous thromboembolism (vte) and major bleeding (mb). specifically, a subsequent analysis of the hokusai study showed that the excess in mb was confined to patients with gastrointestinal cancer. in the riete registry, patients with gastrointestinal or genitourinary cancers experienced more bleeding outcomes while patients with brain or lung cancer experienced more thrombotic outcomes. however, in a subgroup analysis of the caravaggio trial, major gastrointestinal bleeding in patients with crc was low and similar in both apixaban and lmwh groups. patients with crc are underrepresented in the major trials examining treatment of cat with anticoagulant. despite concerns that doacs pose a significant bleeding risk in crc patients, many patients with crc are treated with apixaban or rivaroxaban in clinical practice. balancing risks of thrombosis recurrence and bleeding can be challenging and requires a nuanced, individualized approach to decision making to improve prognosis in this population. the aim of this study is to identify risk factors for recurrence and bleeding in crc patients with vte. deaths, regardless of the mechanism, will also be included in the one year all-cause mortality outcome.

Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed crc and symptomatic or incidental vte who received anticoagulant treatment. 2. crc patients with vte treated with an anticoagulant (rivaroxaban or lmwh) for at least six months. exclusion criteria: 1. participation in this study required active anticoagulant treatment. apart from this, there were no specific exclusion criteria.

Keywords: venous thrombembolism；colorectal cancer；bleeding
trial comparing part-time versus full-time patching for severe amblyopia

Conditions: Amblyopia

Summary: the goals of this study are: * to determine whether the visual acuity improvement obtained with part-time (6 hours) patching is equivalent to the visual acuity improvement obtained with full-time patching (all or all but one waking hour) for severe amblyopia. * to develop more precise estimates than currently available for the visual acuity improvement that occurs during treatment of amblyopia with patching. * to identify factors that may be associated with successful treatment of amblyopia with patching.

amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. patching has been the mainstay of amblyopia therapy. it is generally held that the response to treatment is best when it is instituted at an early age, particularly by age two or three, and is poor when attempted after eight years of age. for severe amblyopia, it is generally accepted that occlusion with patching is the standard of care. other modalities of treatment, such as atropine penalization and optical penalization, are widely considered insufficient as initial treatments for severe amblyopia. however, controversy exists with regard to how many hours per day of patching should be prescribed. advocates of full-time patching purport that such a regimen is needed to restore visual acuity more rapidly and more effectively. advocates of part-time patching believe it to be better tolerated by the child and family, therefore producing less stress on the parent-child relationship and producing better results through better compliance. part-time patching may also promote the development of binocularity in patients who have "straight-eyes", reduce the chance of a straight-eyed patient developing manifest strabismus or losing stereopsis, and reduce the incidence of reverse- or occlusion-amblyopia. the study is a randomized trial comparing daily patching regimes for children with severe amblyopia. it will consist of about 160 children. patients in the severe (20/100 to 20/400) group will patch part-time (6 hours) or full-time (all or all but one waking hour) of each day for the 4 month study period. there are at least two follow up visits during the 4-month period. visual acuity is the major study outcome. it is assessed at the 4-month exam.

Eligibility criteria:
inclusion criteria: * patients must be less than 7 years of age with the original cause of amblyopia as strabismus or anisometropia (a refractive error difference of more than one diopter between the two eyes.) * visual acuity in the amblyopic eye must be between 20/100 and 20/400. * visual acuity in the sound eye of 20/40 or better. * there must be at least 3 lines of acuity difference between the two eyes. exclusion criteria: * patching treatment (other than spectacles) within six months prior to enrollment and other amblyopia treatment of any type used within one month prior to enrollment.
effect of unani medicine for the management of anomalies associated with polycystic ovarian syndrome

Conditions: Comparative Study

Summary: currently available medications for pcos are symptom(s) oriented but have limitations because of its complex pathophysiology. the most preferred drug against pcos is metformin which act as an insulin sensitizer to improve insulin-glucose metabolism and anovulatory cycles in pcos. however, its use is associated with various side effects such as bloating, diarrhea and nausea. thus, it is imperative to explore various other alternatives to combat this gynecological problem.

polycystic ovarian syndrome (pcos) is a common endocrine disorder in reproductive age women, with a prevalence between 5%-15%. currently, sedentary lifestyle, excessive intake of junk food and increasing prevalence of obesity has been associated with rise in the incidence of pcos.

Eligibility criteria:
inclusion criteria no complications record of reproductive system, 4) pcos diagnosed using rotterdam criteria fulfilling any two of the following: (i) menstrual irregularity or oligo-/anovulation, (ii) hyperandrogenism (clinically and/or biochemically), (iii) polycystic appearance on ultrasound exclusion criteria 1) patients with severe adverse drug reactions, 2) record of cardiovascular, diabetes, hepatic and neoplastic disorders or other concurrent medical illnesses, 3) hormonal contraceptive used within 6 months, or anti-obesity drugs within 3 months of the study, 4) irregular menstrual bleeding other than pcos and 5) positive pregnancy test.
emr versus esd for resection of large distal non-pedunculated colorectal adenomas

Conditions: Colorectal Neoplasms

Summary: endoscopic resection of adenomas in the colon is the cornerstone of effective colorectal cancer prevention. endoscopic mucosal resection (emr) is currently the most used technique for resection of large distal colorectal adenomas, however, maintains some important limitations. in large lesions, emr can often only be performed in a piecemeal fashion resulting in relatively low r0-resection rates and high recurrence rates. endoscopic submucosal dissection (esd) is a newer procedure that is more difficult resulting in a longer procedural time, but is promising due to the high en-bloc resection rates and the very low recurrence rates. the aim of this multicenter randomized study is to compare emr and esd with regard to recurrence rates and radical (r0) resection rates, and to put this into perspective against the costs and complication rates of both strategies and the burden perceived by patients on the long term-term.


Eligibility criteria:
inclusion criteria: * non-pedunculated polyp larger than 20 mm in the rectum, sigmoid or descending colon found during colonoscopy * indication for endoscopic treatment * ≥18 years old * written informed consent exclusion criteria: * suspicion of malignancy, as determined by endoscopic findings (invasive kudo pit pattern, hiroshima type c) or proven malignancy at histology * prior endoscopic resection attempt * presence of synchronous distal advanced carcinoma that requires surgical resection * the risk exceeds the benefit of endoscopic treatment, such as patient's with an extremely poor general condition or a very short life expectancy * the inability to provide informed consent

Keywords: emr esd endoscopic mucosal resection endoscopic submucosal resection colorectal adenomas
plasma glucagon-like peptide-1 levels and in-hospital complications in st-segment elevation myocardial infarction

Conditions: STEMI - ST Elevation Myocardial Infarction; Glucagon-like Peptide-1; Bleeding; Complications

Summary: glucagon-like peptide-1 (glp-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making glp-1 agonist a treatment for diabetes and obesity. pre-clinical and clinical studies have demonstrated that glp-1 also has cardio-protection effects. glp-1 agonists is able to improve markers of cardiac function, reduce myocardial infarct size and post-myocardial infarction remodeling in experimental myocardial infarction. and glp-1 infusion improved left ventricular function and increases myocardial salvage in patients with acute myocardial infarction (ami). the investigators' previous study found that glp-1 analogues attenuated ischemia-reperfusion induced apoptosis of stem- and myocardial microvascular endothelial cells, and liraglutide (a glp-1 analog) usage during hospital stay can prevent no-reflow and improve heart function in ami. therefore, the investigators carried out a cohort study to evaluate the association between plasma glp-1 and in-hospital complications in patients with st-segment elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * a diagnosis of stemi and needed pci exclusion criteria: * patients with cancer patients who used dpp4 inhibitor patients who used glp1 analogue
trial to evaluate the efficacy and safety of dapagliflozin in japanese type 2 diabetes mellitus patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to obtain information on efficacy and safety of dapagliflozin in japanese patients with type 2 diabetes. this will be done by comparing the effect of dapagliflozin to placebo when given in oral doses.


Eligibility criteria:
inclusion criteria: * japanese subjects with type 2 diabetes mellitus. * strictly/relatively treatment naïve subjects with hba1c ≥ 7.0% and ≤ 10%, or subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with hba1c ≤ 8%. * provision of informed consent. exclusion criteria: * having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. * the investigator(s) judged that the subject should not participate in the study according to screening test or medical history.

Keywords: type 2 diabetes mellitus japanese phase 2 efficacy safety dapagliflozin
quality of life in patients with auto-inflammatory diseases

Conditions: Hereditary Autoinflammatory Diseases

Summary: this qualitative interview-based study aim to build a tool to assess quality of life in patients (adults or children) suffering from 6 autoinflammatory diseases (fmf, traps, caps, mkd, still and pfapa).

recent understanding of the physiopathological mechanisms that underpin autoinflammatory diseases (aids) allowed a revolution in the therapeutic management of these patients, particularly through the use of biotherapies. however new treatments need to be evaluated by valid tools. aidai score created and validated by our team evaluates activity of 4 autoinflammatory diseases. one of the important components, not explored by the scores currently available, is the impact of these treatments on quality of life (qol) of patients. the existing quality of life scales are not adapted to these recurrent chronic pathologies. throught a qualitative study based on interviews of patients and/ or parents, the investigators aim to build a tool to evaluate qol in patients suffering from 6 aaids :familial mediterranean fever (fmf), mevalonate kinase deficiency (mkd), tumour necrosis factor receptor-associated periodic syndrome (traps), cryopyrin-associated periodic syndromes (caps), still's disease and pfapa syndrome.

Eligibility criteria:
inclusion criteria: * any patient (child and adult) with one of the 6 aids (fmf, traps, mkd or caps, pfapa or still's disease) regardless of the activity of the disease. the diagnosis will have been made by the referring physician according to criteria specific to each aids * volunteer to participate in the study * with at least one parent present at the consultation if it is a child under 18 years old * for minors, agreement of the parents or their legal representative or one of the present parents * information for children as far as their age and condition allow * affiliation to a national health insurance. exclusion criteria: * patient or relative (according to age)refuse to participate. * bad understanding of french. * other chronic inflammatory pathology associated (example: crohn's, spa, uveitis, psoriasis ...)